Johnson & Johnson said on Wednesday it has temporarily paused the rollout of its Varipulse heart device in the United States, ...

Johnson & Johnson stock (NYSE: JNJ) lost about 7% in 2024, underperforming the broader S&P 500 index, which gained 23% for ...

The temporary pause follows reports of four cases of neurovascular events in the US external evaluation study.

Johnson & Johnson pauses U.S. Varipulse cases to investigate neurovascular events. The FDA-approved device integrates PFA ...

Despite the pause, the company clarified that the suspension does not impact commercial activity outside the US.

In that single-arm study, the rate of primary adverse events within 7 days of ablation was 2.9%, with the most common ...

The temporary halt to investigate reported neurovascular events comes two months after Johnson & Johnson won FDA approval for ...

Johnson & Johnson said on Wednesday it temporarily paused the rollout of its Varipulse heart device in the United States as ...

“On January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and ...

The temporary pause will allow the company to investigate four neurovascular events seen in an external validation study.

Johnson & Johnson MedTech (NYSE: JNJ) announced that it received CE mark approval for its dual-energy ThermoCool SmartTouch ...

Johnson & Johnson MedTech has temporarily paused all U.S. external evaluations and cases using its Varipulse pulse field ...